摘要:
Analyte monitoring devices, systems, and methods are provided that relate to: enabling different application features on a data processing device for analyte monitoring devices with different analyte monitoring features; programming analyte monitoring devices in advance; personalizing an analyte monitoring device; graphically representing a remaining insulin level in a user body; and graphically representing analyte measurement related data for on-demand readings; protecting access to feature of an analyte monitoring device.
摘要:
Analyte monitoring devices, systems, and methods are provided that relate to: enabling different application features on a data processing device for analyte monitoring devices with different analyte monitoring features; programming analyte monitoring devices in advance; personalizing an analyte monitoring device; graphically representing a remaining insulin level in a user body; and graphically representing analyte measurement related data for on-demand readings; protecting access to feature of an analyte monitoring device.
摘要:
System and method receive medical data of a patient having a disease afflicted health condition for processing and analysis of that data. Software installed on a health care provider's computer for processing the medical data includes a GUI reimbursement window that informs the HCP of reimbursement possibilities for analysis of the data and counseling of the patient. The reimbursement window also includes hyperlinks and may also include codes for insurance claims. Lists of reimbursement entities, pre-authorization instructions, coding instructions, and contacts may all be included and may be personalized for a particular patient. In one case, a complete bill is created and submitted to an insurance entity. In another, a patient data base is created so that the reimbursement window can inform the HCP of patient analysis frequency, which may affect reimbursement.
摘要:
Safety features are applied to an integrated insulin delivery system to enhance safety while accounting for glucose sensor bias and calibration errors. One safety feature includes comparisons of calibrations of the sensor to nominal sensitivity and taking action, such as limiting insulin delivery or taking a further calibration of the sensor. In another feature, an automatic resumption of a basal delivery rate is programmed into the delivery device to avoid the possibility of complete loss of delivery of insulin in the event that communication with the delivery device is disrupted. Other features include steps taken to avoid hypoglycemia in the event that the sensor is negatively biased.
摘要:
An integrated insulin delivery system having safety features for controlling medication delivery includes automatic resumption of basal rate after a particular event, such as termination of a bolus, expiration of a time period, delayed resumption after the bolus has terminated, IOB comparison, and others. Other safety features include overriding a delivery control that may result in hypoglycemia, terminating an extended bolus or temporary basal rate in view of a glucose signal indicating imminent carbohydrate deficiency, and controlling the delivery rate to take an asymmetrical bias range of a glucose sensor into account to avoid hypoglycemia.
摘要:
An integrated insulin delivery system having safety features for controlling medication delivery includes automatic resumption of basal rate after a particular event, such as termination of a bolus, expiration of a time period, delayed resumption after the bolus has terminated, IOB comparison, and others. Other safety features include overriding a delivery control that may result in hypoglycemia, terminating an extended bolus or temporary basal rate in view of a glucose signal indicating imminent carbohydrate deficiency, and controlling the delivery rate to take an asymmetrical bias range of a glucose sensor into account to avoid hypoglycemia.
摘要:
Safety features are applied to an integrated insulin delivery system to enhance safety while accounting for glucose sensor bias and calibration errors. One safety feature includes comparisons of calibrations of the sensor to nominal sensitivity and taking action, such as limiting insulin delivery or taking a further calibration of the sensor. In another feature, an automatic resumption of a basal delivery rate is programmed into the delivery device to avoid the possibility of complete loss of delivery of insulin in the event that communication with the delivery device is disrupted. Other features include steps taken to avoid hypoglycemia in the event that the sensor is negatively biased.
摘要:
A closed-loop method for insulin infusion overnight uses a model predictive control algorithm (“MPC”). Used with the MPC is a glucose measurement error model which was derived from actual glucose sensor error data. That sensor error data included both a sensor artifacts component, including dropouts, and a persistent error component, including calibration error, all of which was obtained experimentally from living subjects. The MPC algorithm advised on insulin infusion every fifteen minutes. Sensor glucose input to the MPC was obtained by combining model-calculated, noise-free interstitial glucose with experimentally-derived transient and persistent sensor artifacts associated with the FreeStyle Navigator® Continuous Glucose Monitor System (“FSN”). The incidence of severe and significant hypoglycemia reduced 2300- and 200-fold, respectively, during simulated overnight closed-loop control with the MPC algorithm using the glucose measurement error model suggesting that the continuous glucose monitoring technologies facilitate safe closed-loop insulin delivery.